Invested in Pikralida, advancing PKL-021 for stroke neuroprotection and brain injury treatment.
Pikralida is a fast-growing biotechnology company that combines research and development (R&D) activities with Contract Research Organization (CRO) services, creating a unique hybrid business model
Pikralida is a fast-growing biotechnology company that combines research and development (R&D) activities with Contract Research Organization (CRO) services, creating a unique hybrid business model. We specialize in discovering and developing innovative therapeutic solutions. Currently, our flagship project is the development of PKL-021, an active inhibitor of matrix metalloproteinases (MMPs).